These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 35086838)

  • 21. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 23. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
    Mayor S
    BMJ; 2015 May; 350():h2689. PubMed ID: 25990552
    [No Abstract]   [Full Text] [Related]  

  • 25. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
    Mayer M
    Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
    [No Abstract]   [Full Text] [Related]  

  • 26. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 27. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 28. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
    Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
    Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
    [No Abstract]   [Full Text] [Related]  

  • 30. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 31. The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock.
    Tümmler B
    Lancet Respir Med; 2014 Jul; 2(7):508-9. PubMed ID: 24973279
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cystic Fibrosis: toward a genetic treatment; Clostridium difficile versus Clostridium difficile].
    Nau JY
    Rev Med Suisse; 2015 May; 11(476):1210-1. PubMed ID: 26182641
    [No Abstract]   [Full Text] [Related]  

  • 33. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 34. Pulmonology: CFTR modulators for cystic fibrosis.
    Bertoncini E; Colomb-Lippa D
    JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision Medicine: At What Price?
    Ferkol T; Quinton P
    Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
    [No Abstract]   [Full Text] [Related]  

  • 36. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 37. Comment on "Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients".
    Ballmann M; Prinz N; Glass A; Holl R
    J Cyst Fibros; 2020 Sep; 19(5):839. PubMed ID: 32507542
    [No Abstract]   [Full Text] [Related]  

  • 38. Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted.
    Burki TK
    Lancet Respir Med; 2019 Sep; 7(9):739-740. PubMed ID: 31353281
    [No Abstract]   [Full Text] [Related]  

  • 39. Orkambi's Slick Unveiling Puts Insurers in a Bind.
    Silverman E
    Manag Care; 2015 Aug; 24(8):16-7. PubMed ID: 26399136
    [No Abstract]   [Full Text] [Related]  

  • 40. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
    Ramsey BW; Welsh MJ
    Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.